Navigation Links
Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
Date:10/24/2007

nts within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Apollos human proteins boost stem cell research
5. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  Early symptoms of diabetic eye and ... new technology, coupled with yearly, comprehensive eye exams, ... detection of eye diseases, including those associated with ... left untreated, these diseases can potentially lead to ... Recently, optometric researchers have deployed a new tool ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
Breaking Medicine Technology:Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
(Date:10/20/2014)... 20, 2014 The newly updated Worldwide ... of thousands of facts, figures and forecasts on the ... medical sector forecast categories the Worldwide Medical Market ... and national views on the worldwide medical market to ... report gives you data for 2010-2019, covering each country ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... which claim to use subtle energy to stimulate the ... the intensity of pain in a number of conditions, ... in dementia, over and above what standard treatments can ... Jain, from the UCLA Division of Cancer Prevention and ...
... FRANCISCO, Oct. 29 VIA Pharmaceuticals, Inc. (Nasdaq: ... the development of compounds for the treatment of ... Rebecca Taub, Senior Vice President Research & Development ... Targeting Cardiometabolic Disease", and will discuss the Company,s ...
... employers to take heed , THURSDAY, Oct. 29 (HealthDay News) ... it might get worse -- at least for a while. ... report that stress levels peak when people reach their early ... age. , That,s not necessarily good news, either: Work-related ...
... ... Business Journal’s 11th annual award for the health care company category , ... Pompano Beach, FL (PRWEB) October 29, ... Health Care Award in the health care company category. The South Florida Business ...
... found that rheumatoid arthritis (RA) patients did not experience ... after starting anti-tumor necrosis factor (TNF) therapy. The ... Karolinska University Hospital in Stockholm, Sweden assessed the short-term ... therapies: infliximab, adalimumab, and etanercept. Details of the ...
... ... stereotypes , ... Arlington, VA (PRWEB) October 28, 2009 -- As Halloween approaches, the National Alliance ... costumes and other seasonal attractions that feature inaccurate and offensive stereotypes regarding those with ...
Cached Medicine News:Health News:Biofield therapies: Helpful or full of hype? 2Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 2Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 3Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 4Health News:VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference 5Health News:After Age 55, Workplace Stress Seems to Decline 2Health News:American Diabetes Wholesale Wins 2009 Excellence In Health Care Award from South Florida Business Journal 2Health News:Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patients 2Health News:NAMI Issues "Stigma Alert" Over Inaccurate and Offensive Halloween Costumes, Attractions 2Health News:NAMI Issues "Stigma Alert" Over Inaccurate and Offensive Halloween Costumes, Attractions 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: